Articles
Pharmalicensing brings you advice, commentary and analysis from industry experts.
- Articles
- Browse
Articles
In 2004, Worldwide Business Research and Pharmalicensing jointly awarded Endo Pharmaceuticals and Vernalis the BioBusiness Network Innovative Partnership 2004 award More
A neuroscience company focused on developing novel drugs for the treatment of CNS disorders, Amarin's lead product, MiraxionTM, is in development for Huntington's disease and treatment-unresponsive depression More
Related Reports
Market Research Reports provided by reports.iptechex.com
Jun 2006 - 1068 pages - $2,495
Oct 2010 - 53 pages - $1,000
Sep 2011 - 97 pages - $3,500
Feb 2011 - 75 pages - $1,000
Jan 2010 - $75
Nov 2011 - 61 pages - $3,800
Jan 2010 - $75
Jan 2010 - $75
Apr 2008 - 250 pages - $3,995
Jan 2010 - $75
Your selection
- Therapeutic target
- Central Nervous System del
Browse By
- Industry sector
- Academic/Research
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Non-profit org./Government
- Pharmaceutical
- Research tools
- Service
- Therapeutic target
- Age-related disorders (other)
- Amyotrophic lateral sclerosis
- CNS (other)
- Neurodegenerative disorders
- Neurological
- Pain
- Psychiatric
- Subarachnoid hemorrhage
- Traumatic brain injury
- Year
- 2013
- 2012
- 2011
- 2010
- 2009
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
- 2001
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us